SAFETY ASSESSMENT CONSIDERATIONS FOR ANTIBODY DRUG CONJUGATES

被引：0
|
作者：
Hinkle, Beth [1 ]
机构：
[1] Amgen Inc, Thousand Oaks, CA USA
来源：
DRUG METABOLISM REVIEWS | 2012年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：23 / 24
页数：2
相关论文
共 50 条
  • [41] Key considerations based on pharmacokinetic/pharmacodynamic in the design of antibody-drug conjugates
    Gao, Yangyang
    Xia, Yuwei
    Chen, Yixin
    Zhou, Shiqi
    Fang, Yingying
    Yu, Jieru
    Zhang, Leyin
    Sun, Leitao
    FRONTIERS IN ONCOLOGY, 2025, 14
  • [42] Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned
    Alfonso López de Sá
    Cristina Díaz-Tejeiro
    Elisa Poyatos-Racionero
    Cristina Nieto-Jiménez
    Lucía Paniagua-Herranz
    Adrián Sanvicente
    Emiliano Calvo
    Pedro Pérez-Segura
    Víctor Moreno
    Francisco Moris
    Alberto Ocana
    Journal of Hematology & Oncology, 16
  • [43] Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned
    de Sa, Alfonso Lopez
    Diaz-Tejeiro, Cristina
    Poyatos-Racionero, Elisa
    Nieto-Jimenez, Cristina
    Paniagua-Herranz, Lucia
    Sanvicente, Adrian
    Calvo, Emiliano
    Perez-Segura, Pedro
    Moreno, Victor
    Moris, Francisco
    Ocana, Alberto
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2023, 16 (01)
  • [44] Antibody-Drug Conjugates in the Pipeline for Treatment of Melanoma: Target and Pharmacokinetic Considerations
    Lami, Ina
    Wiemer, Andrew J.
    DRUGS IN R&D, 2024, 24 (02) : 129 - 144
  • [45] Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations
    Shim, Hyunbo
    BIOMOLECULES, 2020, 10 (03)
  • [46] ADME Considerations and Bioanalytical Strategies for Pharmacokinetic Assessments of Antibody-Drug Conjugates
    Mou, Si
    Huang, Yue
    Rosenbaum, Anton I.
    ANTIBODIES, 2018, 7 (04):
  • [47] Pathophysiologic and Pharmacologic Considerations to Improve the Design and Application of Antibody-Drug Conjugates
    Boghaert, Erwin R.
    Cox, Megan C.
    Vaidya, Kedar S.
    CANCER RESEARCH, 2022, 82 (10) : 1858 - 1869
  • [48] Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
    D'Arienzo, Andrea
    Verrazzo, Annarita
    Pagliuca, Martina
    Napolitano, Fabiana
    Parola, Sara
    Viggiani, Martina
    Caputo, Roberta
    Puglisi, Fabio
    Giuliano, Mario
    Del Mastro, Lucia
    Arpino, Grazia
    De Laurentiis, Michelino
    Montemurro, Filippo
    ECLINICALMEDICINE, 2023, 62
  • [49] Optimizing the safety of antibody-drug conjugates for patients with solid tumours
    Tarantino, Paolo
    Ricciuti, Biagio
    Pradhan, Shan M.
    Tolaney, Sara M.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (08) : 558 - 576
  • [50] Advances in Linker Technology: Improving the Safety and Efficacy of Antibody Drug Conjugates
    Challener, Cynthia A.
    BIOPHARM INTERNATIONAL, 2014, 27 (03) : 22 - +
12345